107_CD Alliance_NNP UniChem_NNP Plc_NNP 47_CD RELATED_NNP PARTY_NNP DISCLOSURES_NNP Subsidiary_NNP undertakings_NNS The_DT consolidated_JJ financial_JJ statements_NNS include_VBP the_DT financial_JJ statements_NNS of_IN Alliance_NNP UniChem_NNP Plc_NNP and_CC its_PRP$ subsidiary_NN undertakings_NNS ._.
The_DT principal_JJ subsidiary_NN undertakings_NNS all_DT of_IN which_WDT were_VBD indirectly_RB held_VBN were_VBD :_: Interest_NN in_IN ordinary_JJ share_NN capital_NN and_CC Country_NN of_IN Country_NN of_IN voting_NN rights_NNS operation_NN incorporation_NN Main_NNP activity_NN Northern_NNP Europe_NNP Wholesale_JJ UniChem_NNP Limited_NNP 100_CD %_NN UK_NNP UK_NNP pharmaceutical_JJ wholesaler_NN Interpharm_NNP B._NNP V._NNP 100_CD %_NN The_DT Netherlands_NNPS The_DT Netherlands_NNP pharmaceutical_JJ wholesaler_NN Alliance_NNP UniChem_NNP CZ_NNP Spo_NNP 97.1_CD %_NN Czech_JJ Republic_NNP Czech_JJ Republic_NNP pharmaceutical_JJ wholesaler_NN Holtung_NNP A._NNP S._NNP 100_CD %_NN Norway_NNP Norway_NNP pharmaceutical_JJ wholesaler_NN Southern_NNP Europe_NNP Wholesale_JJ Alliance_NNP Sant_NNP S._NNP A._NNP 99.8_CD %_NN France_NNP France_NNP pharmaceutical_JJ wholesaler_NN Alleanza_NNP Salute_NNP Italia_NNP SpA_NNP 100_CD %_NN Italy_NNP Italy_NNP pharmaceutical_JJ wholesaler_NN and_CC holding_VBG company_NN Safa_NNP Galenica_NNP S._NNP A._NNP 99.2_CD %_NN Spain_NNP Spain_NNP pharmaceutical_JJ wholesaler_NN Alloga_NNP S._NNP A._NNP 100_CD %_NN Europe_NNP Luxembourg_NNP holding_VBG company_NN for_IN a_DT number_NN of_IN pre-wholesalers_NNS Retail_NNP E._NNP Moss_NNP Limited_NNP 100_CD %_NN UK_NNP UK_NNP retail_JJ pharmacy_NN operator_NN Alliance_NNP UniChem_NNP Norge_NNP A._NNP S._NNP 100_CD %_NN Norway_NNP Norway_NNP retail_JJ pharmacy_NN operator_NN fide_NN Vier_NNP Vijzels_NNP B._NNP V._NNP 100_CD %_NN The_DT Netherlands_NNPS The_DT Netherlands_NNP retail_JJ pharmacy_NN operator_NN As_IN permitted_VBN by_IN Section_NN 231_CD 5_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, only_RB principal_JJ undertakings_NNS are_VBP shown_VBN ._.
A_DT complete_JJ list_NN of_IN all_DT subsidiary_NN undertakings_NNS is_VBZ filed_VBN with_IN the_DT Companys_NNP annual_JJ return_NN ._.
Transactions_NNS between_IN the_DT Company_NN and_CC its_PRP$ subsidiaries_NNS ,_, which_WDT are_VBP related_VBN parties_NNS ,_, have_VBP been_VBN eliminated_VBN on_IN consolidation_NN and_CC are_VBP not_RB disclosed_VBN in_IN this_DT note_NN ._.
Associates_NNPS The_DT Groups_NNS principal_JJ associates_NNS were_VBD :_: Interest_NN in_IN ordinary_JJ share_NN capital_NN and_CC Country_NN of_IN Country_NN of_IN voting_NN rights_NNS operation_NN incorporation_NN Main_NNP activity_NN 1_CD Alliance_NNP UniChem_NNP Farmacutica_NNP S._NNP A._NNP 49_CD %_NN Portugal_NNP Portugal_NNP pharmaceutical_JJ wholesaler_NN 2_CD Andreae-Noris_NNP Zahn_NNP AG_NNP 29.99_CD %_NN Germany_NNP Germany_NNP pharmaceutical_JJ wholesaler_NN 3_CD Galenica_NNP A._NN G._NNP 25.5_CD %_NN Switzerland_NNP Switzerland_NNP pharmaceutical_JJ wholesaler_NN Hedef_NNP Alliance_NNP Holding_NNP A._NNP S._NNP 50_CD %_NN Turkey_NNP Turkey_NNP pharmaceutical_JJ wholesaler_NN Pharmapartners_NNP B._NNP V._NNP 40_CD %_NN The_DT Netherlands_NNPS The_DT Netherlands_NNP pharmaceutical_JJ software_NN UniDrug_NNP Distribution_NN Group_NNP Limited_NNP 50_CD %_NN UK_NNP UK_NNP pre-wholesaler_JJ Unifarma_NNP Distribuzione_NNP S._NNP r._NNP l._VBD 36_CD %_NN Italy_NNP Italy_NNP pharmaceutical_JJ wholesaler_NN 1_CD The_NNP Group_NNP previously_RB owned_VBD 100_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN of_IN Alliance_NNP UniChem_NNP Farmacutica_NNP S._NNP A._NNP 51_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN was_VBD disposed_VBN of_IN during_IN the_DT year_NN ._.
2_CD The_DT accounting_NN reference_NN date_NN for_IN Andreae-Noris_NNP Zahn_NNP AG_NNP is_VBZ 31_CD August_NNP ._.
3_CD All_DT shares_NNS have_VBP the_DT same_JJ voting_NN rights_NNS ,_, but_CC no_DT shareholder_NN may_MD exercise_VB more_JJR than_IN 20_CD %_NN of_IN the_DT votes_NNS ._.
Trading_NN transactions_NNS with_IN associated_VBN undertakings_NNS ,_, all_DT of_IN which_WDT are_VBP carried_VBN out_RP on_IN an_DT arms_NNS length_NN basis_NN were_VBD :_: 2005_CD 2004_CD Revenue_NN Balance_NNP Revenue_NNP Balance_NNP in_IN year_NN at_IN year_NN end_NN in_IN year_NN at_IN year_NN end_NN million_CD million_CD million_CD million_CD Sales_NNS Alloga_NNP S._NNP A._NN and_CC subsidiaries_NNS 2.0_CD 0.1_CD Pharmacy_NNP Initiative_NNP 1_CD Plc_NNP 1.8_CD 0.3_CD 1.9_CD 0.2_CD Pharmacy_NNP Initiative_NNP 2_CD Plc_NNP 1.4_CD 0.3_CD 1.4_CD 0.2_CD Pharmacy_NNP Initiative_NNP 3_CD Plc_NNP 0.6_CD 0.1_CD 0.6_CD 0.1_CD 2005_CD 2004_CD Purchases_NNPS Balance_NNP Purchases_NNPS Balance_NNP in_IN year_NN at_IN year_NN end_NN in_IN year_NN at_IN year_NN end_NN million_CD million_CD million_CD million_CD Purchases_NNP Alloga_NNP S._NNP A._NN and_CC subsidiaries_NNS 0.2_CD 97.1_CD 0.5_CD Unifarma_NNP Distribuzione_NNP S._NNP r._NNP l._VBD 0.2_CD
